Oncology

Latest News

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com
Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

August 29th 2025

The 6-month progression-free survival rate for the combination therapy was 52.2%.

For rent sign | Image Credit: David Gales - stock.adobe.com
Housing Assistance May Help Renters With Cancer Better Withstand Medical Financial Strain

August 28th 2025

Patient with cancer undergoing chemotherapy | Image credit: RFBSIP – stock.adobe.com
Many Patients With Advanced Cancer Report Care Misaligned With Their Goals

August 25th 2025

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap
Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

August 21st 2025

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
June 13th 2013

Supreme Court Rules: No Patents for Human Genes

Site Logo
June 10th 2013

Immunotherapy Cancer Drugs Are Breakthrough, But Cost Is An Issue

Site Logo
June 7th 2013

More Cancer Specialist Nurses To Improve Hospital Care

Site Logo
June 6th 2013

PSA Screening: New Round Of Guidelines Emphasizes Importance Of Weighing Harms And Benefits

Site Logo
June 5th 2013

Trends in Patient Chemo Care Add Strain to Medicare

Dr. George Addresses Provider Issues Regarding Immunotherapies
June 3rd 2013

Dr. George Addresses Provider Issues Regarding Immunotherapies

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.
Dr. Kolodziej Discusses Personalized Medicine in Oncology
June 3rd 2013

Dr. Kolodziej Discusses Personalized Medicine in Oncology

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting.
Penn Survey Finds Cancer Drug Shortages Affect Treatment, Research
June 3rd 2013

Penn Survey Finds Cancer Drug Shortages Affect Treatment, Research

Ongoing shortages of common oncology chemotherapies have compelled physicians to substitute more expensive drugs, delay or suspend clinical trials, or even skip doses of chemotherapy, according to survey results gathered by a team from the University of Pennsylvania.
Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy
June 2nd 2013

Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment.
Dr. Andrew Seidman Discusses the Management of Patients With Brain Metastases
June 2nd 2013

Dr. Andrew Seidman Discusses the Management of Patients With Brain Metastases

Over the 20 years I've been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress, said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.
Phase III Study Finds Kidney-Cancer Drug Prevents Relapses of Ovarian Cancer
June 2nd 2013

Phase III Study Finds Kidney-Cancer Drug Prevents Relapses of Ovarian Cancer

Ovarian cancer survivors could have an option for treatment after chemotherapy, based on the outcome of a phase III study of an approved oral therapy for kidney cancer and soft tissue sarcoma.
In Phase II Study, Combination Therapy Extends Survival, Reduces Side Effects in Metastatic Melanoma Patients
June 2nd 2013

In Phase II Study, Combination Therapy Extends Survival, Reduces Side Effects in Metastatic Melanoma Patients

Two-thirds of the metastatic myeloma patients in a phase II study were still alive a year after receiving a new combination therapy, compared to slightly more than half of patients receiving a standard monotherapy for the cancer, according to results presented today at the 49th Annual meeting of the American Society of Clinical Oncology in Chicago.
Dr. George Talks About New Data on Checkpoint Inhibitors
June 2nd 2013

Dr. George Talks About New Data on Checkpoint Inhibitors

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013.
Long-Term Study Affirms Link Between Cardiovascular Fitness, Lower Cancer Risk in Men
May 31st 2013

Long-Term Study Affirms Link Between Cardiovascular Fitness, Lower Cancer Risk in Men

This finding makes it clear that patients should be advised that they need to achieve a certain fitness level, and not just be told that they need to exercise. Unlike patient-reported exercise behavior, Lakoski said, fitness can be objectively and accurately measured in a clinical setting.
Results Show Idelalisib May Offer Option Where Few Exist for CLL Patients
May 31st 2013

Results Show Idelalisib May Offer Option Where Few Exist for CLL Patients

Half the patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who were treated with idelalisib in a phase I study experienced rapid and prolonged tumor shrinkage, a promising finding given the limited treatment choices for this group.
Early Signs of Promise as Yale's Herbst Details PD-L1 Immunotherapy Data
May 30th 2013

Early Signs of Promise as Yale's Herbst Details PD-L1 Immunotherapy Data

Results detailed today offer hope that a new form of immunotherapy will propel the bodies of some cancer patients to fight tumors, not be overrun by them, according to a study outlined at the Annual Meeting of the American Society of Clinical Oncologists (ASCO) in Chicago.
Less is More: Researchers Surprised by Radiotherapy Results Involving Locally Advanced NSCLC
May 30th 2013

Less is More: Researchers Surprised by Radiotherapy Results Involving Locally Advanced NSCLC

Patients in a phase III trial lived longer and experienced fewer treatment-related deaths from locally advanced non-small cell lung cancer (NSCLC) after receiving the standard dose of radiotherapy, compared to those receiving a high dose, according to a study presented today at the Annual Meeting of the American Society of Clinical Oncologists (ASCO).
Symptoms, Not Scans, Offer Better Measure of Relapse for DLBCL Patients
May 30th 2013

Symptoms, Not Scans, Offer Better Measure of Relapse for DLBCL Patients

Imaging spotted relapses for just a tiny fraction of patients with diffuse large B-cell lymphoma (DLBCL) before symptoms appeared, according to a new multi-institutional study, prompting recommendations that the radiation exposure of follow-up scans may not be worthwhile for all patients.
Site Logo
May 23rd 2013

Can Cancer Patients Seeking a Second Opinion Get Better Care?

Hui-Ru Chang, PhD Ming-Chin Yang, DrPH Kuo-Piao Chung, PhD
Colorectal resection patients in Taiwan with heavy hospital shopping behaviors got better surgical care than those who did not shop or hospitals.
Site Logo
May 23rd 2013

Medicare Nixes Coverage For New Cancer Tests

Site Logo
May 22nd 2013

New Research Proves Clinical Pathways Can Reduce Cancer Care Costs and Improve Quality While Increasing Physician Reimbursement

Site Logo
May 13th 2013

Variability in Resource Use: Diagnosing Colorectal Cancer

F. Douglas Srygley, MD David H. Abbott, BA, MS Steven C. Grambow, PhD Dawn Provenzale, MD, MS Robert S. Sandler, MD, MPH Deborah A. Fisher, MD, MHS
In a cohort of 449 patients with colorectal cancer in the VA health system, diagnostic resource use varied with facility, patient age, and patient presentation.
Site Logo
May 8th 2013

Oncology Practice Leaders Refocusing Efforts to Improve Long Term Viability

Site Logo
May 7th 2013

Chemoprevention in Prostate Cancer: Identifying Patients at Greatest Risk May Provide Greatest Value

Marj P. Zimmerman, MS, BS Pharm Stanton R. Mehr
Site Logo
May 7th 2013

Performance Metrics in Oncology

Thomas R. Barr, MBA
Site Logo
May 7th 2013

Applying Accountable Care to Oncology: Developing an Oncology ACO

Stanton R. Mehr
The cost-saving potential of specialty or disease-specific ACOs can be huge...but it is unclear whether these specialty services are more efficiently provided through their own ACO or as ancillary to the burgeoning primary care ACO marketplace.
Site Logo
May 7th 2013

Five Trends Emerge in Payer Management of Oncology

Susan Weber
Market Dynamics Change How Plans Manage Oral and Office-Administered Agents
Site Logo
May 7th 2013

Measuring Quality Cancer Care

Robert Gamble
Site Logo
May 7th 2013

Bundled Payment: Practice Savior or Killer?

Kurt Ullman
As payment reform models continue to evolve, practitioners must determine which strategy makes the most sense for their practice. Although the idea behind bundled payments may be worth considering, there are some concerns that this system could causes disruptions in oncology practices.
Site Logo
May 7th 2013

Value-Based Contracting for Pharmaceuticals: Getting Ready for Prime Time?

Stanton R. Mehr
<1
...
175176177178179180181182183
...
188>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo